Trial Radar
Sign in

Study record

A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)

A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)

NCT06841354

RecruitingPhase 3

Sponsor: Merck Sharp & Dohme LLC

Conditions: Triple Negative Breast Neoplasms

Interventions: Sacituzumab tirumotecan, Pembrolizumab, Rescue Medication, Paclitaxel, Nab-paclitaxel

Countries: United States, Argentina, Australia, Belgium, Brazil, Canada, Chile, China

Researchers want to know if sacituzumab tirumotecan given alone or with pembrolizumab can treat triple negative breast cancer (TNBC). The main goal of this study is to learn if people treated with sacituzumab tirumotecan alone or with pembrolizumab live longer overall or without the cancer growing or spreading compared to people treated with chemotherapy.

Study history thread

Detected changes and registry snapshots from Trial Radar syncs

2 events · 2 snapshots

2 recorded events2 registry snapshotsTracked since Jul 13, 2026Official CT.gov history
  1. Aug 29, 2026
    LocationMinor

    Merck Sharp & Dohme LLC expanded into Ukraine

    Sites added: Ukraine

    Registry state after update: Recruiting · Phase 3 · 35 countries

  2. Jul 13, 2026
    New TrialNotable

    Merck Sharp & Dohme LLC started Phase 3 Triple Negative Breast Neoplasms trial

    Registry state after update: Recruiting · Phase 3 · 35 countries

Snapshot progression

  1. Aug 29, 2026Recruiting · Phase 3 · 35 countries
  2. Jul 13, 2026Recruiting · Phase 3 · 34 countries

← Back to dashboard